Showing 1–16 of 24 results
Detect Herpes Simplex Virus (HSV) I & II with PCR testing for accurate diagnosis. Fast, reliable results for effective treatment and management.
Sample Type : EDTA
Methodology : Real-time PCR
TAT : 10 Days
Adenovirus DNA, Quantitative Real-Time PCR is a highly sensitive and specific molecular diagnostic test designed for the rapid and accurate quantification of adenovirus DNA in clinical samples. Utilizing real-time PCR technology, it ensures precise viral load measurement, enabling early detection and effective monitoring of infections.
Sample Type : Stool
Methodology : Real-time PCR
TAT : 10 Days
ALK Fusion – FISH is a fluorescence in situ hybridization (FISH) test designed to detect ALK gene rearrangements in tumor samples, primarily for non-small cell lung cancer (NSCLC) patients. Key features include high sensitivity and specificity, FDA approval for clinical diagnostics, and direct visualization of ALK gene fusions at the cellular level.
The Bacterial Vaginosis DNA, Quant, RT-PCR test is an advanced molecular diagnostic tool designed for the accurate detection and quantification of bacterial vaginosis (BV)-associated pathogens. Utilizing real-time PCR (RT-PCR) technology, it provides rapid, precise, and quantitative analysis of key bacterial species linked to BV, including Gardnerella vaginalis, Atopobium vaginae, and others.
Sample Type : Vaginal Swab
Methodology : Real-time polymerase chain reaction (PCR)
TAT : 3 Days
The BCR/ABL – Quantitative test is a highly sensitive molecular diagnostic assay used to detect and quantify the BCR-ABL fusion gene, a key biomarker in chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). Utilizing real-time PCR technology, it provides precise measurement of BCR-ABL transcript levels, enabling accurate disease monitoring and treatment response assessment.
Sample Type : Whole Blood
Methodology : Real time PCR
TAT : 8-10 Days
Beta Thalassemia by PCR is a molecular diagnostic test designed to detect mutations in the HBB gene responsible for beta thalassemia.
Sample Type : EDTA Whole Blood
Methodology : PCR
TAT : 4 Weeks
Sample Type : Whole Blood
Methodology : Conventional Cytogenetics: Culture + Chromosome analysis
TAT : 30 Days
The HPV PCR (40 genotypes) test is a comprehensive molecular diagnostic tool that detects and identifies 40 different genotypes of the Human Papillomavirus (HPV), including both high-risk and low-risk strains. Utilizing advanced PCR technology, it offers high sensitivity and specificity for early and accurate detection.
Sample Type : Swab/LBC/Urine
Methodology : PCR
TAT : 3 days
The Comprehensive Stool PCR is an advanced diagnostic test that uses multiplex polymerase chain reaction (PCR) technology to rapidly and accurately detect a wide range of gastrointestinal pathogens, including bacteria, viruses, and parasites, from a single stool sample.
Sample Type : Stool
Methodology : Flow Cytometry
TAT : 15 Days
The Fragile X (FMR1) Mutation Screen (L) is a genetic test designed to detect mutations in the FMR1 gene, which are associated with Fragile X syndrome, a leading cause of inherited intellectual disability and autism. This screening identifies CGG repeat expansions, distinguishing between normal, premutation, and full mutation alleles. Key benefits include early detection for informed reproductive decisions, risk assessment for carriers, and guidance for personalized medical management. Utilizing advanced molecular techniques, the test ensures high accuracy and reliability. Ideal for individuals with a family history of Fragile X or unexplained developmental delays, this screening provides critical genetic insights for proactive healthcare planning.
The Hepatitis B Virus – Qualitative (PCR) test is a highly sensitive molecular diagnostic tool designed to detect the presence of Hepatitis B viral DNA in a patient’s blood. Utilizing advanced Polymerase Chain Reaction (PCR) technology, it offers early and accurate detection of active HBV infection, even at low viral loads.
Sample Type : 4 mL EDTA plasma or Serum
Methodology : Real-time PCR
TAT : 2 Days
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment.
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
Sample Type : Serum
Methodology : Electrophoresis
TAT : 10 Days
Sample Type : Whole Blood
Methodology : Real-time PCR
TAT : 10 Days
